ArticleAnnals of clinical and translational neurology2026
Life-Threatening Bradycardia in Anti-NMDA-Receptor Encephalitis and a Novel Use for Permanent Pacing.
Article in Annals of clinical and translational neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Autoimmune Encephalitis in Acute Care-Pathology, Diagnosis, and Management.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundPediatric anti-NMDA receptor encephalitis (pNMDARE) is an autoantibody-mediated disorder that can cause severe autonomic dysfunction, including symptomatic bradycardia and asystole. Dysautonomia can last for years, making it very challenging to manage.
objectiveTo describe outcomes of 5 pNMDARE patients with life-threatening bradycardic and/or asystolic events who were managed with permanent or semi-permanent pacemaker implantation.
methodsWe performed a retrospective chart review of 5 patients from multiple institutions. We included patients with a diagnosis of pNMDARE (confirmed by positive cerebrospinal fluid and/or serum anti-NMDAR antibodies) who had a permanent or semi-permanent pacemaker placed due to symptomatic bradycardia, sinus pauses, and/or asystole. Assessed outcomes included mortality, the presence of additional bradycardic/asystolic events after pacemaker implantation, pacemaker complications (lead/device infection, device malfunction), and the ongoing need for ventricular pacing.
resultsFour patients had permanent pacing systems placed, and one patient had a semi-permanent pacemaker placed. Three patients required continued intermittent ventricular pacing months to years after disease onset. None of the patients had further episodes of symptomatic bradycardia or asystole after pacemaker implantation. One patient, who had a severe, intractable form of pNMDARE, died after discontinuing immunotherapies; she had multiple pacemaker interrogations that demonstrated no sign of pacemaker dysfunction.
conclusionPermanent and semi-permanent pacemakers are a safe, effective management strategy for cases of pNMDARE with prolonged courses of severe bradycardia and/or asystole.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.